Suppr超能文献

肝外门静脉血栓形成:病因及生存的决定因素

Extrahepatic portal vein thrombosis: aetiology and determinants of survival.

作者信息

Janssen H L, Wijnhoud A, Haagsma E B, van Uum S H, van Nieuwkerk C M, Adang R P, Chamuleau R A, van Hattum J, Vleggaar F P, Hansen B E, Rosendaal F R, van Hoek B

机构信息

Department of Gastroenterology and Hepatology, University Hospital Rotterdam, The Netherlands.

出版信息

Gut. 2001 Nov;49(5):720-4. doi: 10.1136/gut.49.5.720.

Abstract

BACKGROUND

Malignancy, hypercoagulability, and conditions leading to decreased portal flow have been reported to contribute to the aetiology of extrahepatic portal vein thrombosis (EPVT). Mortality of patients with EPVT may be associated with these concurrent medical conditions or with manifestations of portal hypertension, such as variceal haemorrhage.

PATIENTS AND METHODS

To determine which variables have prognostic significance with respect to survival, we performed a retrospective study of 172 adult EPVT patients who were followed over the period 1984-1997 in eight university hospitals.

RESULTS

Mean follow up was 3.9 years (range 0.1-13.1). Overall survival was 70% (95% confidence interval (CI) 62-76%) at one year, 61% (95% CI, 52-67%) at five years, and 54% (95% CI, 45-62%) at 10 years. The one, five, and 10 year survival rates in the absence of cancer, cirrhosis, and mesenteric vein thrombosis were 95% (95% CI 87-98%), 89% (95% CI 78-94%), and 81% (95% CI 67-89%), respectively (n=83). Variables at diagnosis associated with reduced survival according to multivariate analysis were advanced age, malignancy, cirrhosis, mesenteric vein thrombosis, absence of abdominal inflammation, and serum levels of aminotransferase and albumin. The presence of variceal haemorrhage and myeloproliferative disorders did not influence survival. Only four patients died due to variceal haemorrhage and one due to complications of a portosystemic shunt procedure.

CONCLUSION

We conclude that mortality among patients with EPVT is related primarily to concurrent disorders leading to EPVT and not to complications of portal hypertension.

摘要

背景

据报道,恶性肿瘤、高凝状态以及导致门静脉血流减少的情况均与肝外门静脉血栓形成(EPVT)的病因有关。EPVT患者的死亡率可能与这些并存的内科疾病或门静脉高压的表现(如静脉曲张出血)相关。

患者与方法

为确定哪些变量对生存具有预后意义,我们对1984年至1997年期间在8所大学医院接受随访的172例成年EPVT患者进行了一项回顾性研究。

结果

平均随访时间为3.9年(范围0.1 - 13.1年)。1年时总体生存率为70%(95%置信区间(CI)62 - 76%),5年时为61%(95% CI,52 - 67%),10年时为54%(95% CI,45 - 62%)。在无癌症、肝硬化和肠系膜静脉血栓形成的情况下,1年、5年和10年生存率分别为95%(95% CI 87 - 98%)、89%(95% CI 78 - 94%)和81%(95% CI 67 - 89%)(n = 83)。根据多变量分析,诊断时与生存降低相关的变量为高龄、恶性肿瘤、肝硬化、肠系膜静脉血栓形成、无腹部炎症以及血清转氨酶和白蛋白水平。静脉曲张出血和骨髓增殖性疾病的存在不影响生存。仅4例患者死于静脉曲张出血,1例死于门体分流手术并发症。

结论

我们得出结论,EPVT患者的死亡率主要与导致EPVT的并存疾病有关,而非门静脉高压的并发症。

相似文献

1
Extrahepatic portal vein thrombosis: aetiology and determinants of survival.
Gut. 2001 Nov;49(5):720-4. doi: 10.1136/gut.49.5.720.
3
Changing perspectives in portal vein thrombosis.
Scand J Gastroenterol Suppl. 2000(232):69-73.
5
A comparative clinical study of idiopathic portal hypertension, extrahepatic portal vein thrombosis, and cirrhosis.
J Clin Gastroenterol. 1994 Oct;19(3):217-21. doi: 10.1097/00004836-199410000-00010.
6
Ascites in patients with noncirrhotic nonmalignant extrahepatic portal vein thrombosis.
Aliment Pharmacol Ther. 2010 Aug;32(4):529-34. doi: 10.1111/j.1365-2036.2010.04375.x. Epub 2010 May 22.

引用本文的文献

1
Incidence, risk factors and outcomes for post-hepatectomy portal vein thrombosis: A retrospective study.
World J Gastrointest Surg. 2025 Jun 27;17(6):104729. doi: 10.4240/wjgs.v17.i6.104729.
2
Endovascular management of acute portal vein thrombosis in pediatric liver transplant recipients less than 20 kg.
Pediatr Radiol. 2025 May;55(5):957-964. doi: 10.1007/s00247-025-06189-3. Epub 2025 Feb 14.
3
Splenectomy unveils thrombocytosis in underlying myeloproliferative neoplasms with extrahepatic portal vein obstruction.
Intractable Rare Dis Res. 2024 Aug 31;13(3):165-171. doi: 10.5582/irdr.2024.01013.
4
Asymptomatic Extrahepatic Portal Venous Obstruction: A Case Report.
Cureus. 2024 Jul 7;16(7):e64037. doi: 10.7759/cureus.64037. eCollection 2024 Jul.
6
Portal Vein Thrombosis (PVT) Secondary to Protein C Deficiency in a Young Male.
Cureus. 2023 Nov 29;15(11):e49688. doi: 10.7759/cureus.49688. eCollection 2023 Nov.
7
Splanchnic Vein Thrombosis in Myelofibrosis-An Underappreciated Hallmark of Disease Phenotype.
Int J Mol Sci. 2023 Oct 29;24(21):15717. doi: 10.3390/ijms242115717.
8
Portal Vein Thrombosis in Patients with Liver Cirrhosis: What Went Wrong?
Int J Gen Med. 2023 Aug 28;16:3889-3906. doi: 10.2147/IJGM.S413438. eCollection 2023.
9
Long term prophylactic anticoagulation for portal vein thrombosis after splenectomy: A systematic review and meta-analysis.
PLoS One. 2023 Aug 15;18(8):e0290164. doi: 10.1371/journal.pone.0290164. eCollection 2023.
10
Budd-Chiari syndrome in myeloproliferative neoplasms: A review of literature.
World J Clin Oncol. 2023 Mar 24;14(3):99-116. doi: 10.5306/wjco.v14.i3.99.

本文引用的文献

2
Portal vein thrombosis in adults: pathophysiology, pathogenesis and management.
J Hepatol. 2000 May;32(5):865-71. doi: 10.1016/s0168-8278(00)80259-7.
4
Venous thrombosis: a multicausal disease.
Lancet. 1999 Apr 3;353(9159):1167-73. doi: 10.1016/s0140-6736(98)10266-0.
6
Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation.
Lancet. 1994 Nov 26;344(8935):1453-7. doi: 10.1016/s0140-6736(94)90286-0.
7
Extrahepatic portal hypertension. A retrospective analysis of 127 cases and associated clinical implications.
Arch Surg. 1974 Mar;108(3):338-41. doi: 10.1001/archsurg.1974.01350270068012.
8
Management of extrahepatic portal hypertension in children.
Ann Surg. 1974 Oct;180(4):487-93. doi: 10.1097/00000658-197410000-00014.
9
Portal thrombosis in cirrhotics. A retrospective analysis.
Ann Surg. 1986 Mar;203(3):286-91. doi: 10.1097/00000658-198603000-00012.
10
Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders.
Gastroenterology. 1988 Apr;94(4):1063-9. doi: 10.1016/0016-5085(88)90567-7.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验